Wave Life Sciences released updated clinical data from its phase Ib/IIa study for WVE-006, an RNA editing therapy aimed at alpha-1 antitrypsin deficiency (AATD). The data demonstrated sustained production of corrected alpha-1 antitrypsin protein levels associated with reduced liver and lung disease risk. However, despite confirming biological activity, the results fell short of outperforming competitors, leading to a declining stock market response. The ongoing trial evaluates multiple dosing regimens, informing further development of RNA editing approaches for rare genetic diseases.